Skip to main content
. 2017 Feb 28;36:36. doi: 10.1186/s13046-017-0509-1

Fig. 1.

Fig. 1

CONSORT diagram. Scheme showing an HLA-A-status double-blind, biologically randomized phase II study of three therapeutic epitope peptides combined with gemcitabine as a first-line therapy for advanced pancreatic cancer (VENUS-PC study)